Table 1.
Sabbag et al.33 | van Welsenes et al30 | Aonuma et al.37 | Kabutoya et al.51 | Kotake et al.31 | Yokoshiki et al.36 | Cho et al.4 | Park et al.32 | |
---|---|---|---|---|---|---|---|---|
n | 2,349 | 2,134 | 171 | 392 | 985 | 17,564 | 305 | 146 |
Year | 2015 | 2011 | 2022 | 2021 | 2021 | 2020 | 2020 | 2017 |
Country | Israel | the Netherlands | Japan | Japan | Japan | Japan | Korea | Korea |
Primary/secondary, % | 75/25 | 61/39 | 100/0 | 42/58 | 54/46 | 26/74 | 55/45 | 25/75 |
ICM/NICM, % | 84/16 | 70/30 | 42/58 | 100/0 | 42/58 | 36/64 | 43/57 | 50/50 |
Appropriate ICD therapy/ICD shock | 3.9/1.1 (1 y) | 37 (5 y)/20 (5 y) | 10 (24 mo)/NA | 20 (20 mo)/9 (20 mo) | 22 (36 mo)/NA | NA | 18/12 (31 mo) | NA/39 (42 mo) |
ICD = implantable cardioverter-defibrillator; ICM = ischemic cardiomyopathy; NA = not available; NICM = nonischemic cardiomyopathy.